NCT04874207View on ClinicalTrials.gov

Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib

PHASE4CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

April 11, 2025

Study Completion Date

April 11, 2025

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Regorafenib

Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15

Trial Locations (9)

Unknown

CHU Caen, Caen

AP-HP Henri Mondor, Créteil

Institut Daniel Hollard, Groupe Hospitalier Mutualiste de Grenoble, Grenoble

CHU Nantes, Nantes

AP-HP St Antoine, Paris

Centre Eugène Marquis, Rennes

CHU Rennes, Rennes

CHU Rouen, Rouen

CHU Tours, Tours

All Listed Sponsors

lead

Rennes University Hospital

OTHER

NCT04874207 - Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib | Biotech Hunter | Biotech Hunter